Anti–vascular endothelial growth factor (anti-VEGF) agents have become the standard of care in neovascular age-related macular degeneration (nAMD). Despite generally excellent response rates to anti-VEGF therapy, some patients do not respond or may respond suboptimally. In the case of refractory or rapidly recurring fluid in nAMD, clinicians may switch to another anti-VEGF agent. TITAN was an observational study that assessed the effectiveness and safety of intravitreal aflibercept (IVT-AFL) in patients with nAMD refractory to ranibizumab who switched to IVT-AFL after less than 12 months of ranibizumab treatment in routine clinical practice in France.
Methods
TITAN was an observational, retrospective and prospective 12-month study conducted at 28 centres in France. Patients with nAMD refractory to ranibizumab were enrolled. Patients who were switched from ranibizumab to IVT-AFL were followed for 12 months. Data were obtained from medical records for retrospectively included patients, and at routine follow-up visits for those included prospectively. The main outcome measure was percentage of patients who achieved treatment success (gain of ≥1 Early Treatment Diabetic Retinopathy Study letters in best-corrected visual acuity [BCVA] and/or any reduction in central retinal thickness [CRT]) from baseline to 12 months after switching. A sample size of 225 patients was determined based on a 2-sided 95% confidence interval with a width equal to 0.12 when the sample proportion was 0.70.
Results
We analysed safety data (N = 217) and clinical outcomes from patients in the per-protocol population (n = 125). The mean (standard deviation) number of IVT-AFL injections was 7.5 (2.6). Treatment success was achieved in 68.8% of patients. Mean BCVA change from baseline to Month 12 was + 1.5 letters (P = 0.105) and the mean CRT change was − 45.0 μm (P < 0.001). In a subgroup analysis, in patients who received three initial monthly IVT-AFL injections, mean BCVA gain was 3.3 letters at Month 12 (P = 0.015). Excluding lack of efficacy and inappropriate scheduling of drug administration, the most common adverse event was eye pain (2.3%).
Conclusions
Switching ranibizumab-refractory patients with nAMD to IVT-AFL may improve visual outcomes in some patients, particularly those who receive three initial monthly injections.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Abkürzungen
AE
Adverse event
anti-VEGF
Anti-vascular endothelial growth factor
BCVA
Best-corrected visual acuity
CRT
Central retinal thickness
ETDRS
Early Treatment Diabetic Retinopathy
FAS
Full analysis set
IRF
Intraretinal fluid
IVT-AFL
Intravitreal aflibercept
LOCF
Last observation carried forward
nAMD
Neovascular age-related macular degeneration
PP
Per-protocol
SAS
Safety analysis set
SD
Standard deviation
SRF
Subretinal fluid
sub-RPE
Subretinal pigment epithelium
Background
Neovascular age-related macular degeneration (nAMD) is the most severe form of AMD and is the most common cause of legal blindness [1, 2]. Anti–vascular endothelial growth factor (anti-VEGF) agents, including intravitreal aflibercept (IVT-AFL) and ranibizumab, have become standard of care in nAMD [3‐8]. Despite generally excellent response rates to anti-VEGF therapy, some patients do not respond or may respond suboptimally [3‐8]. Some studies have shown reduced anatomic response over time with ranibizumab treatment in patients with nAMD, and there have been reports of loss of bioefficacy after repeated ranibizumab treatment [9‐11].
In the case of refractory or rapidly recurring fluid in nAMD, clinicians may switch from the current anti-VEGF agent to another anti-VEGF agent [12]. The VIEW 1 and VIEW 2 studies [13] assessed the efficacy and safety of IVT-AFL in patients with nAMD and demonstrated non-inferiority of IVT-AFL 2 mg, given every 8 weeks after three initial monthly doses, versus ranibizumab 0.5 mg, every 4 weeks, in maintaining vision (loss of < 15 Early Treatment Diabetic Retinopathy [ETDRS] letters in best-corrected visual acuity [BCVA]) in treatment-naïve patients over a 12-month period [14‐17].
Anzeige
Retrospective studies have shown that individualised IVT-AFL treatment can significantly reduce retinal fluid and preserve vision in patients with nAMD who are resistant to anti-VEGF agents [17‐20]. However, prospective studies examining a switch to IVT-AFL in patients refractory to ranibizumab treatment in a real-world setting are scarce [21].
TITAN was an observational study that assessed the effectiveness and safety of IVT-AFL in patients with nAMD refractory to ranibizumab (persistence of intraretinal [IRF] and/or subretinal fluid [SRF]) who switched to IVT-AFL after less than 12 months of ranibizumab treatment in routine clinical practice in France.
Methods
Study design
TITAN (NCT02321241) was an observational 12-month study to assess the effectiveness and safety of IVT-AFL in patients with nAMD refractory to ranibizumab. The study was conducted in 28 centres in France and enrolled patients both retrospectively and prospectively. Data were analysed from patients who received IVT-AFL treatment between January 1, 2014 and December 31, 2015. The date of the first IVT-AFL injection was considered the baseline visit, and data collection continued for a maximum of 12 months after the first injection. For retrospectively enrolled patients, the number of office visits, eye exams and treatments were collected from medical records; for prospectively enrolled patients, this information was recorded at routine follow-up visits. The study protocol was approved by a French data privacy committee (Comité Consultatif sur le Traitement de l’Information en Matière de Recherche dans le Domaine de la Santé and Commission Nationale de l’Informatique et des Libertés). All patients provided written informed consent to participate.
Participants
Patients diagnosed with nAMD who had been treated with ranibizumab for > 3 but < 12 months and switched to prescribed IVT-AFL by their physician were included. Eligible patients must have been refractory to ranibizumab, defined as persistent IRF and/or SRF on optical coherence tomography despite treatment with ranibizumab, in accordance with the Haute Autorité de Santé recommendations of at least three injections of ranibizumab.
Anzeige
Patients excluded from the study were those with any ranibizumab-treated eyes for nAMD previously switched to IVT-AFL, absence of treatment criteria for IVT-AFL, eyes previously treated with photodynamic therapy, another retinal disease (diabetic retinopathy, diabetic macular oedema, myopia or angioid streaks) or participation in any interventional study.
The safety analysis set (SAS) included all patients who received ≥1 IVT-AFL treatment in any eye. The per-protocol (PP) population was defined as all patients in the full analysis set (FAS) (i.e., BCVA ≥35 letters at baseline, or delay of ≤380 days between first and last ranibizumab injection, or ≥ 3 ranibizumab injections), with BCVA and central retinal thickness (CRT) assessments prior to any treatment (including ranibizumab), at baseline, and at Month 12. The FAS included patients who received ≥1 IVT-AFL treatment and had BCVA and CRT assessments in the study eye at baseline and during follow-up. Patients from the FAS who received a BCVA/CRT assessment before any treatment (including ranibizumab) at enrolment and at Month 12 were included in the subgroup analysis. This subset of patients was stratified by whether or not they received three initial monthly IVT-AFL injections following the switch.
Outcomes
The primary endpoint was treatment success rate at 12 months (defined as a gain of ≥1 letter in BCVA and/or any decrease in CRT [in μm] between initial visit [first injection of IVT-AFL] and 12-month follow-up visit). BCVA was measured using ETDRS letters (preferentially) or any other visual scale. For data analysis, we transformed any other visual acuity score to ETDRS letter score.
Secondary outcomes included change in BCVA between baseline and final study visits (12 months after the first injection of IVT-AFL or study discontinuation), mean duration of ranibizumab treatment before initiation of IVT-AFL, and frequency and mean number of IVT-AFL injections over the study period. No BCVA data were collected at the end of ranibizumab treatment; however, switching to IVT-AFL occurred relatively soon after the last ranibizumab injection (median of 44.0 days). Therefore, the change in BCVA during ranibizumab treatment was estimated based on the change between BCVA values before any treatment and before first injection of IVT-AFL.
All adverse events (AEs) occurring after the first IVT-AFL injection were documented in the electronic case report form. All patient medical records were evaluated for demographic as well as clinical characteristics, and AEs were summarised using the Medical Dictionary for Regulatory Activities coding system. The event rates for single AEs were calculated based on the total number of documented patients and AEs were categorised according to connection with medication, seriousness, discontinuation of therapy and outcome.
Statistical analyses
A sample size of 225 patients was determined based on a 2-sided 95% confidence interval (CI) with a width equal to 0.12 when the sample proportion was 0.70. Primary analysis criteria (success rate) considered patients who discontinued IVT-AFL treatment prematurely to be treatment failures. We expressed the incidence of treatment success at 12 months as number and percentage of patients (n [%]) and provided a 2-sided 95% CI.
The main analysis of secondary criteria (BCVA and CRT) was performed without replacing missing values at study end. Change in BCVA (ETDRS letters) was expressed as mean (standard deviation [SD]) and provided a 2-sided 95% CI. We performed two sensitivity analyses with two imputation methods for missing data: imputation of missing value by the last observation carried forward (LOCF) method and imputation of missing data with the median value of population. Statistical analyses were conducted with SAS software release 9.4 (SAS Institute Inc., Cary, NC, USA).
Results
Participants
A total of 236 patients were screened. Of these, 217 were included in the SAS and 125 were included in the PP population (Fig. 1). Demographic characteristics are shown in Table 1.
Fig. 1
Patient disposition. *Three initial monthly injections (− 1/+ 2 weeks). The per-protocol population was defined as patients without protocol deviation and with BCVA/CRT assessments prior to any treatment (ranibizumab) at baseline and at Month 12 (n = 125). The FAS included patients who received ≥1 IVT-AFL treatment and had BCVA and CRT assessments in the study eye at baseline and during follow-up (n = 185). BCVA = best-corrected visual acuity; CRT = central retinal thickness; FAS = full analysis set; IVT-AFL = intravitreal aflibercept; SAS = safety analysis set
Table 1
Demographic Characteristics
Full Analysis Set
(n = 185)
Per-Protocol Set
(n = 125)
Characteristic at baseline
Age, years
77.6 (8.5)
78.2 (8.0)
Female, n (%)
109 (58.9)
79 (63.2)
Duration of nAMD, months
8.5 (7.3)
7.4 (3.3)
Characteristic before any treatment, including ranibizumab
BCVA, ETDRS letters
62.4 (16.6)a
64.0 (15.6)
CRT, μm
368.3 (124.4)b
362.4 (115.2)c
Subretinal fluid, n (%)
133 (76.9)b
92 (74.2)c
Intraretinal fluid, n (%)
76 (43.9)b
55 (44.4)c
Pigment epithelium detachment, n (%)
125 (72.3)b
88 (71.0)c
Mean (standard deviation) unless otherwise stated
an = 163; bn = 161; cn = 116; values correspond to assessments before any treatment, including ranibizumab, had been administered
BCVA Best-corrected visual acuity, CRT Central retinal thickness, ETDRS Early Treatment Diabetic Retinopathy Study, nAMD Neovascular age-related macular degeneration
×
Anzeige
Ranibizumab treatment and outcomes prior to switching
Treatment with ranibizumab was initiated soon after diagnosis of nAMD, with a mean lapse of < 1 month (Table 2). Approximately 75% of patients had their first injection of ranibizumab < 0.3 months after diagnosis of nAMD. Patients received a mean (SD) of 5.1 (2.5) injections over 5.6 (4.3) months [22]. Approximately 50% of patients received ≥4 ranibizumab injections over a median duration of 4.6 months. Mean (SD) BCVA improved significantly with ranibizumab treatment prior to the switch (+ 2.2 [12.0] ETDRS letters, P = 0.046) (Table 2). Distribution of patients with SRF, IRF and subretinal pigment epithelium (sub-RPE) at baseline according to the absence or presence of SRF, IRF and sub-RPE before treatment (including ranibizumab), is shown in Fig. 2.
Table 2
Ranibizumab Treatment and Outcomes Before Switch to Intravitreal Aflibercept
Patients
(n = 125)
Delay between diagnosis of nAMD and first injection of ranibizumab, months
0.5 (1.2)
Number of ranibizumab injections
4.8 (1.9)
Duration of ranibizumab treatment, months
4.9 (2.8)
BCVA before any treatment (including ranibizumab), ETDRS letters
64.0 (15.6)
BCVA at baseline (switch to IVT-AFL), ETDRS letters
66.2 (12.1)
Change in BCVA from before the start of any treatment (including ranibizumab) and baseline (switch to IVT-AFL)
2.2 (12.0)
P value
0.046
All values are expressed as mean (standard deviation); per-protocol population
Proportion of patients with SRF, IRF and sub-RPE. At baseline (prior to switch) (a) and at Month 12 (following switch) (b). IRF = intraretinal fluid; SRF = subretinal fluid; sub-RPE = sub-retinal pigment epithelium. Any treatment includes ranibizumab. *Twelve patients without SRF at baseline were found with SRF at least once over the follow-up and three of them switched from IVT-AFL to ranibizumab. †Twenty-three patients without IRF at baseline were found with IRF at least once over the follow-up and one of them switched from IVT-AFL to ranibizumab. ‡Thirteen patients without sub-RPE fluid at baseline were found with sub-RPE fluid at least once over the follow-up and two of them switched from IVT-AFL to ranibizumab
×
Intravitreal aflibercept treatment and outcomes following the switch
The success rate (proportion of patients with a gain of ≥1 letter in BCVA and/or any decrease in CRT [in μm] between baseline [the date of the first IVT-AFL injection] and 12-month follow-up visit) was 68.8%. The mean BCVA improvement from baseline to Month 12 was 1.5 letters (P = 0.105) (Table 3). At Month 12, 55.2% of patients (n = 69/125) were able to read ≥70 letters.
Table 3
Intravitreal Aflibercept Treatment and Outcomes Following Switch to Intravitreal Aflibercept
Patients
(n = 125)
Delay between last injection of ranibizumab and first IVT-AFL, days
61.2 (46.1)
Reasons for switch to IVT-AFL, n (%)
Refractory
122 (97.6%)
AE/SAE
3 (2.4%)
Other
0 (0%)
Time between diagnosis of nAMD and first IVT-AFL, months
7.4 (3.3)
Duration of IVT-AFL treatment, months
11.3 (3.1)
Follow-up duration, months
12.7 (2.0)
Number of IVT-AFL injections
7.5 (2.6)
BCVA, ETDRS letters
Baseline (switch to IVT-AFL)
66.2 (12.1)
Month 12
67.7 (13.6)
Change in BCVA score between baseline and 12 months
1.5 (10.3)
P value
0.105
CRT, μm
Baseline (switch to IVT-AFL)
331.2 (103.3)
Month 12
286.2 (84.7)
Change in CRT between baseline and 12 months
−45.0 (101.1)
P value
< 0.001
Patients with SRF,n (%)
Baseline
87 (70.7)
Month 12
58 (48.3)
Patients with IRF,n (%)
Baseline
44 (35.8)
Month 12
27 (22.5)
All values are reported as mean (standard deviation) unless otherwise indicated; per-protocol population
Data on the timing of first injection, treatment duration and number of IVT-AFL injections are shown in Table 3. Given the presence of extreme values, the median data is presented instead of the mean. The delay between the last injection of ranibizumab and the first IVT-AFL injection ranged from 9 to 314 days (mean [SD], 61.2 [46.1]; median 43 days). The main reason for switching from ranibizumab to IVT-AFL was that the patient was considered refractory to ranibizumab.
The range of IVT-AFL treatments received over the 12-month study duration is shown in Fig. 3. More than half of patients (52.8%) received three initial monthly IVT-AFL injections. Overall, 17.6% (n = 22) of patients switched at least once from IVT-AFL to ranibizumab, and 5.6% (n = 7) switched back to IVT-AFL.
Fig. 3
Distribution of number of intravitreal aflibercept injections over the 12-month study. Per-protocol population. IVT-AFL = intravitreal aflibercept
×
Anzeige
Anatomic outcomes following the switch
Anatomic outcomes improved in patients who were refractory to ranibizumab and switched to IVT-AFL (Table 3). Mean CRT reduction from baseline to Month 12 was 45.0 μm (P < 0.001). The proportion of patients with SRF at baseline was 70.7% (n = 87/123) and at Month 12 was 48.3% (n = 58/120). The proportion of patients with IRF was 35.8% at baseline (n = 44/123) and 22.5% (n = 27/120) at Month 12, respectively. Differences between the proportions of patients with and without fluid at baseline and Month 12 were significant for SRF and IRF (McNemar test P < 0.001 and P = 0.014, respectively), but not sub-RPE. Distribution of patients with SRF, IRF and sub-RPE at Month 12 according to the absence or presence of SRF, IRF and sub-RPE at baseline are shown in Fig. 2.
Approximately one-quarter of patients (24.0%; n = 30/125) gained 0 to 4 letters; 16.8% (n = 21/125) gained 5 to 9 letters; 10.4% (n = 13/125) gained 10 to 14 letters; and 11.2% (n = 14/125) gained ≥15 letters from baseline to Month 12. Among patients gaining ≥15 letters, mean BCVA change was 20.6 (8.0) letters. Conversely, 8.0% (n = 10/125) lost ≥15 letters. Figure 4 shows the distribution of patients by final absolute BCVA subgroups (< 50; 50 to 55; 55 to 70; and ≥ 70 letters).
Fig. 4
Distribution of patients by absolute final BCVA subgroups (< 50, 50–55, 55–70 and ≥ 70 letters). *n = 125. Per-protocol population. BCVA = best–corrected visual acuity
×
Exploratory and subgroup analyses following switch
In an exploratory analysis conducted in the PP population, patients with < 3 months of ranibizumab treatment prior to baseline gained a mean (SD) of 4.0 (11.1) letters from baseline to Month 12 (P = 0.025). This gain was greater than that observed in patients with 3 to 5 months, 6 to 8 months, and ≥ 9 months of ranibizumab treatment prior to baseline (+ 0.1 [10.8], − 0.6 [8.2] and + 2.1 [7.8] letters, respectively) (Supplementary Fig. 1).
In a subgroup analysis in the FAS population (patients with BCVA/CRT assessment before any treatment [including ranibizumab], at baseline and at Month 12), the overall success rate was 66.7%, with higher rates in patients who received three initial monthly IVT-AFL injections compared with those who did not (69.0% vs 64.1%, respectively; Table 4). No statistical test was performed, but 95% CIs largely overlap.
Table 4
Success Rate by Use or Non-use of 3 Initial Monthly Injections (FAS Population)
Overall
(n = 135)
With 3 initial monthly injections
(n = 71)
Without 3 initial monthly injections
(n = 64)
Success rate at 12 months,a
n (%) [95% CI]
90 (66.7)
[58.0–74.5]
49 (69.0)
[56.9–79.5]
41 (64.1)
[51.1–75.7]
BCVA, ETDRS letters
Baseline
65.1 (13.7)
63.6 (12.3)
66.9 (15.1)
Month 12
66.9 (15.0)
66.8 (12.1)
66.9 (17.8)
Change in BCVA between initial visit and 12 months
1.7 (10.5)
3.3 (11.0)
0.0 (9.6)
P value
0.056
0.015
NS
CRT, μm
Baseline
328.0 (100.9)
338.6 (114.6)
316.3 (82.5)
Month 12
285.3 (84.3)
296.1 (88.0)
272.6 (78.6)
Change in CRT between initial visit and 12 months
−47.0 (104.1)
−45.5 (106.0)
−48.8 (102.6)
P value
< 0.001
< 0.001
< 0.001
All values are reported as mean (standard deviation) unless otherwise indicated
P values are for the paired samples t test
aPatients who gained ≥1 ETDRS letter (BCVA) and/or a reduction in CRT from baseline (prior to switch) to 12 months after the first intravitreal aflibercept injection
BCVA Best–corrected visual acuity, CI Confidence interval, CRT Central retinal thickness, ETDRS Early Treatment Diabetic Retinopathy Study, FAS Full analysis set, NS Not significant
Anzeige
At Month 12, in patients who received three initial monthly IVT-AFL injections, mean BCVA gain was 3.3 letters (P = 0.015). Mean BCVA was stable in patients who did not receive three initial monthly injections (Table 4). There was a trend in favour of higher BCVA gains among patients with lower initial BCVA.
Sensitivity analyses
Results of the sensitivity analyses were consistent with the results of the main analyses. Specifically, the success rate in the overall population was 68.8% when we replaced missing data by the median of the population, or by LOCF. Mean (SD) gain in BCVA was 1.5 (10.3) letters (P = 0.105) when missing data were replaced by the median of the population, or by LOCF. At Month 12, the proportion of patients who could read ≥70 letters was 55.2% for median value replacement and for LOCF value replacement.
Safety outcomes
Excluding lack of efficacy and inappropriate scheduling of drug administration, which were also considered AEs according to the protocol and occurred in 12.4 and 5.1% of patients, respectively, the most common AE was eye pain (2.3%) (Table 5). Treatment-emergent serious AEs were reported in 1.8% of patients, none associated with IVT-AFL treatment. The most common non-ocular AE was falls, occurring in 1.4% of patients. Twenty-seven patients discontinued IVT-AFL due to lack of efficacy and a further seven discontinued IVT-AFL due to other treatment-emergent AEs; in two patients, the AEs (both PED, one with retinal exudate) were considered related to IVT-AFL.
Discussion
Results from the TITAN study indicate that approximately two-thirds (67.7%) of patients with nAMD who switched from ranibizumab to IVT-AFL treatment (after ≤12 months of treatment with ranibizumab) achieved success, defined as a gain of ≥1 letter in BCVA and/or any decrease in CRT between baseline and Month 12. Patients considered refractory to first-line treatment with ranibizumab had an additional gain (beyond the mean 2.2 letters initially achieved with ranibizumab) of 1.5 letters at Month 12 after IVT-AFL treatment was initiated, indicating that switching from ranibizumab to IVT-AFL can be considered in ranibizumab-refractory nAMD. There was an inverse relationship between baseline BCVA and visual acuity gain at Month 12. Generally, patients with lower baseline BCVA had greater visual acuity gains at Month 12. Patients who had previously received ranibizumab for < 3 months prior to switch had a greater improvement in BCVA. In addition to decreases in CRT after switching treatment, an enhanced anatomic response was observed, with reductions in fluid accumulation observed in the SRF, IRF and sub-RPE compartments. Overall, these results suggest that considering a switch to IVT-AFL from ranibizumab after < 3 months may be warranted; however, these findings should be interpreted with caution as the TITAN study was not specifically designed to answer this question, and other confounding variables such as duration of disease are likely to have had an effect.
Findings from other studies of patients refractory to ranibizumab, who switched to IVT-AFL after varying durations of treatment, suggest that there may be a benefit to switching, particularly with anatomical benefit after the switch in terms of improvements in central retinal thickness and pigment epithelium detachment [23]. In fact, the effect of switching on functional outcomes has been shown to be variable [23] and, in our analysis, the overall mean change in BCVA was relatively small. However, over 20% of the ranibizumab-refractory patients achieved BCVA gains of ≥10 letters after receiving IVT-AFL, suggesting there may be specific subgroups of patients who could respond particularly well to switching to IVT-AFL, despite an initially poor response to anti-VEGF therapy with ranibizumab. Further randomised, controlled studies with appropriate control groups are, however, required.
The present study highlights the importance of three initial monthly injections at the start of IVT-AFL treatment. Greater visual improvements were observed in patients who received three initial monthly injections than in those who did not, which is consistent with previous studies of patients with nAMD who were switched from ranibizumab to IVT-AFL [21, 24]. It is notable that the proportion of patients who received three initial monthly injections in TITAN was lower (52.8%) than expected given the recommended dosing regimen in France [25]. Findings from this study were consistent with the known safety profile of IVT-AFL in nAMD [13, 26].
A few limitations inherent in the observational study design should be noted, including the use of different charts to evaluate visual acuity. Here, ETDRS letter charts or any other visual scale were used to evaluate visual acuity; if the latter, results were converted to ETDRS letters, potentially introducing a bias, especially when measuring the number of letters gained or lost after treatment. Also, our study design includes both retrospective and prospective components, and lacks a control group, which is a fundamental aspect of an observational study. In addition, findings are from a single European country, which may not be representative of other countries. Some data were imputed due to variability in data collection; a feature common in observational studies. Given that success was not achieved if patients discontinued IVT-AFL prematurely, even if they switched back to IVT-AFL at a later point, the proportion of patients achieving success may have been underestimated. The success rate was 70.3% (FAS) using median data. Patients who switched from IVT-AFL prior to receiving 12 months of treatment were considered failures; therefore, replacement of missing data by median value of population only slightly affected the success rate. Finally, factors that could influence differences in visual and anatomic outcomes between groups (e.g., disease severity at baseline, frequency of injections and physician monitoring) were not explored in the TITAN study.
Conclusions
The TITAN study demonstrated the effectiveness and safety of IVT-AFL in patients with ranibizumab-refractory nAMD in routine clinical practice in France. These findings suggest that an early switch (< 12 months) from ranibizumab to IVT-AFL may improve visual outcomes over 12 months for some patients in this difficult-to-treat population. The study further highlighted that initiating IVT-AFL treatment with three initial monthly injections after switching from ranibizumab may improve visual outcomes. Further studies with appropriate control groups are required to understand how to best identify those patients most likely to benefit from switching to IVT-AFL.
Acknowledgements
The authors wish to thank the TITAN study investigators: Dr. Aouizerate, Dr. Averous, Professor Baillif, Dr. Benouaich, Dr. Benyelles, Professor Berrod, Dr. Cantaloube-Bessière, Dr. Chahed, Professor Chiambaretta, Dr. Cohen, Dr. Coscas, Dr. De Bats, Dr. Deudon-Combe, Dr. Dominguez, Dr. Donati, Professor Dot, Dr. Dumas, Dr. Giocanti-Auregan, Dr. Guigui, Professor Kodjikian, Dr. Oubraham, Dr. Rothschild, Dr. Rumen, Dr. Sampo, Dr. Scholtès, Dr. Sibille-Dabadie, Professor Souied, Dr. Stanescu, Dr. Tran, Dr. Uzzan, Dr. Wolff and Dr. Zerbib.
Medical writing assistance was provided by Apothecom, UK, and was funded by Bayer Consumer Care AG, Basel, Switzerland.
Ethics approval and consent to participate
Bayer France received a positive statement from the CCTIRS (Comité Consultatif sur le Traitement de l’Information en Matière de Recherche dans le Domaine de la Santé: Advisory Committee on Information Processing in Material Research in the Field of Health) on 26 November 2014 and an authorization from the CNIL (Commission Nationale de l’Informatique et des Libertés: National Commission on Computer Technology and Freedom) on 24 December 2015 concerning the TITAN study. These gave Bayer the possibility to collect, analyse and use anonymised data of patients included in this study. All patients provided written informed consent to participate.
Consent for publication
Not applicable.
Competing interests
SR: Consulting fees from Allergan, Bayer and Novartis; LK: Financial support from Novartis, Allergan, Bayer, Thea and Alcon; consulting fees from Alcon, Alimera, Allergan, Bayer, Roche and Novartis; research funding from Alcon, Alimera, Allergan, Bayer, Horus, Novartis and Thea Pharmaceuticals; AGA: Consulting fees from Alimera, Allergan, Bayer and Novartis; ID: Employee of Bayer HealthCare SAS; ES: Consulting fees and financial support from Allergan, Bayer, Novartis, Roche and Thea Pharmaceuticals.
Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Orbitale und periokuläre metastatische Tumoren galten früher als sehr selten. Aber mit der ständigen Aktualisierung von Medikamenten und Nachweismethoden für die Krebsbehandlung werden neue Chemotherapien und Strahlenbehandlungen eingesetzt. Die …
Metastasen bösartiger Erkrankungen sind die häufigsten Tumoren, die im Auge diagnostiziert werden. Sie treten bei ungefähr 5–10 % der Patienten mit soliden Tumoren im Verlauf der Erkrankung auf. Besonders häufig sind diese beim Mammakarzinom und …
Wird ein Glaukom chirurgisch behandelt, ist die anschließende Wundheilung von entscheidender Bedeutung. In diesem CME-Kurs lernen Sie, welche Pathomechanismen der Vernarbung zugrunde liegen, wie perioperativ therapiert und Operationsversagen frühzeitig erkannt werden kann.
Peri- sowie intraokuläre Metastasen sind insgesamt gesehen selten und meist Zeichen einer fortgeschrittenen primären Tumorerkrankung. Die Therapie ist daher zumeist palliativ und selten kurativ. Zudem ist die Therapiefindung sehr individuell. Die …
Update Augenheilkunde
Bestellen Sie unseren Fach-Newsletterund bleiben Sie gut informiert.
